https://scholars.lib.ntu.edu.tw/handle/123456789/452731
標題: | Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: A Taiwanese Gynecologic Oncology Group study | 作者: | CHI-AN CHEN Lin H. Weng C.-S. Wen K.-C. Lu C.-H. Chou H.-H. Huang Y.-F. Kang C.-Y. Ho C.-M. Yu M.-H. Chou C.-Y. |
公開日期: | 2014 | 卷: | 3161 | 期: | 3167 | 起(迄)頁: | 3161-3167 | 來源出版物: | European Journal of Cancer | 摘要: | Background The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed. Patients and methods Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed. Results The estimated rate of no evidence of disease was 94.0% for 204 patients with adjuvant BEP regimen. Seven grade 3/4 haematological adverse effects including four subjects with neutropenia, one with pancytopenia and two with neutropenic fever were recorded in the 853 total courses of chemotherapeutic cycles. The rates of haematological and non-haematological adverse effects were 0.82% and 2.3%, respectively. No treatment-related mortality was noted. In the analysis of prognostic factors, only tumour stage had a significant impact on disease recurrence (95% confidence interval (CI), 4.2-94.4, p < 0.001) and disease-related mortality (95% CI, 2.2-163.9, p = 0.007). Conclusions The current 3-day adjuvant BEP regimen was effective and safe for patients with MOGCTs. ? 2014 Elsevier Ltd. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/452731 | DOI: | 10.1016/j.ejca.2014.10.006 | SDG/關鍵字: | bleomycin; cisplatin; etoposide; antineoplastic agent; bleomycin; cisplatin; etoposide; adjuvant chemotherapy; adolescent; adult; Article; bone marrow suppression; bronchospasm; cancer combination chemotherapy; cancer mortality; cancer prognosis; cancer recurrence; cancer staging; carcinoid; choriocarcinoma; disease severity; drug efficacy; drug fever; dysgerminoma; febrile neutropenia; female; follow up; germ cell tumor; human; ileus; lung toxicity; major clinical study; malignant ovarian germ cell tumor; malignant ovarian germ cell tumor; malignant teratoma; multiple cycle treatment; nausea and vomiting; nephrotoxicity; neutropenia; onset age; ototoxicity; ovary cancer; ovary teratoma; pancytopenia; postoperative care; postoperative period; priority journal; pyrexia idiopathica; Raynaud phenomenon; seizure; sleep disorder; Taiwanese; treatment duration; treatment outcome; urinary tract infection; yolk sac tumor; aged; clinical trial; conservative treatment; middle aged; mortality; multicenter study; multimodality cancer therapy; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; prognosis; retrospective study; young adult; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organ Sparing Treatments; Ovarian Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。